Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. (Record no. 30427558)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01211 a2200361 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518074359.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 202106s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1476-5454 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1038/s41433-019-0745-z |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Sharma, Ashish |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20210618 |
| 245 00 - TITLE STATEMENT | |
| Title | Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Eye (London, England) |
| Date of publication, distribution, etc. | 06 2020 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1008-1009 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biosimilar Pharmaceuticals |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Substitution |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Infliximab |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Ranibizumab |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hafeez Faridi, M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kumar, Nilesh |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Parachuri, Nikulaa |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sharma, Rohini |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kuppermann, Baruch D |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bandello, Francesco |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Loewenstein, Anat |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Regillo, Carl D |
| 773 0# - HOST ITEM ENTRY | |
| Title | Eye (London, England) |
| Related parts | vol. 34 |
| -- | no. 6 |
| -- | p. 1008-1009 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1038/s41433-019-0745-z">https://doi.org/10.1038/s41433-019-0745-z</a> |
| Public note | Available from publisher's website |
No items available.